Feprazone

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Feprazone 具有抗炎和抗脂肪形成特性。非普拉宗可用于治疗关节和肌肉疼痛的研究。

Feprazone possesses anti-inflammatory and antiadipogenic properties. Feprazone can be used in studies about the treatment of joint and muscular pain.(In Vitro):Lipid accumulation, elevated production of triglycerides, the release of glycerol, upregulated SREBP-1C, FABP4, PPAR-γ, and C/EBP-α and downregulated ATGL and AQP-7 in the 3 T3-L1 adipocytes induced by the adipocyte differentiation cocktail medium were significantly reversed by treatment with Feprazone(30 and 60 μM).

Feprazone (2.5-10 μM; 48 h) rescues cell viability of FFAs-stimulated human aortic endothelial cells (HAECs).Feprazone (5, 10 μM; 24 h) reduces ROS production in HAECs to only 2.4- and 1.6-fold at 5 and 10 μM, respectively, while 300 μM FFA increases ROS production by 3.4-fold; also decreases the mRNA expression and secretion of cytokines CCL5, IL-6, and IL-8, as well as MMP-2 and MMP-9.Feprazone (5, 10 μM; 6 h) decreases TLR4 and MyD88 activities, as well as reduces the phosphorylation of p65 and subsequent activation of NF-κB.Feprazone (30 and 60 μM; 7 days) suppresses the adipogenesis in differentiating 3 T3-L1 cells;reduced the triglyceride content and increased lipolysis during 3 T3-L1 adipogenesis. Cell Viability Assay Cell Line:HAECs (stimulated with 300 μM FFAs)Concentration:2.5, 5 and 10 μMIncubation Time:48 h Result:Rescued cell viability to 81 and 93% of baseline at 5 and 10 μM, while FFAs reduced the cell viability to 63% of baseline.RT-PCR Cell Line:HAECs (stimulated with 300 μM FFAs)Concentration:5 and 10 μM Incubation Time:24 hResult:Decreased the mRNA expression and secretion of cytokines CCL5, IL-6, and IL-8 in a dose-dependent manner.Dose-dependently mitigated the VCAM-1 and ICAM-1 expression to only 1.7- and 1.8-fold, respectively, while FFA increased to 2.8- and 3.4-fold, respectively.Western Blot Analysis Cell Line:HAECs (stimulated with 300 μM FFAs)Concentration:5 and 10 μM Incubation Time:6 h Result:Decreased TLR4 and MyD88 expression, as well as reduced the phosphorylation of p65 and subsequent activation of NF-κB.

Significantly inhibited the adipocyte size, the visceral adipocyte tissue weights and the average bodyweights in HFD mice. Animal Model:Male C57BL/6 N mice [high-fat diet (HFD) induced obesity model Dosage:75 mg/kg Administration:(no described in the research)Result:The visceral adipocyte tissue weights of mice in the control, HFD, and HFD + Feprazone groups were 0.38, 3.51, and 2.37 g, respectively.The average bodyweights of mice in the control, HFD, and HFD + Feprazone groups were 29.6, 41.3, and 34.1 g, respectively.

DA-2370 | DA 2370 | DA2370 | Prenazone

Others

Other Targets

——

——

——

30748-29-9

320.392

C20H20N2O2

>98% (HPLC)

——

CC(C)=CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years